Comparative genomic hybridisation array and DNA sequencing to direct treatment of metastatic breast cancer: a multicentre, prospective trial (SAFIR01/UNICANCER)
Fabrice André, Thomas Bachelot, Frédéric Commo et al. · The Lancet Oncology · 2014
Cited by 404 works. doi:10.1016/s1470-2045(13)70611-9
Authors
- Fabrice André
- Thomas Bachelot
- Frédéric Commo
- Mario Campone
- Mónica Arnedos
- Veronique C Dieras
- Magali Lacroix‐Triki
- Ludovic Lacroix
- Pascale A. Cohen
- David Gentien
- José Adélaı̈de
- Florence Dalenc
- Anthony Gonçalvès
- Christelle Lévy
- Jean-Marc Ferrero
- Jacques M Bonneterre
- Claudia Plesse Lefeuvre
- Marta Jimenez
- Thomas Filleron
- Herve R. Bonnefoi
References
- Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2
- Optimal two-stage designs for phase II clinical trials
- Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing
- The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity
- American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer
- The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups
- Breast Cancer Statistics
- A faster circular binary segmentation algorithm for the analysis of array CGH data
- The landscape of cancer genes and mutational processes in breast cancer
- A transforming mutation in the pleckstrin homology domain of AKT1 in cancer